Research advances in endometriosis-related signaling pathways: A review - 17/06/23
Abstract |
Endometriosis (EM) is characterized by the existence of endometrial mucosa outside the uterine cavity, which causesinfertility, persistent aches, and a decline in women's quality of life. Both hormone therapies and nonhormone therapies, such as NSAIDs, are ineffective, generic categories of EM drugs. Endometriosis is a benign gynecological condition, yet it shares a number of features with cancer cells, including immune evasion, survival, adhesion, invasion, and angiogenesis. Several endometriosis-related signaling pathways are comprehensively reviewed in this article, including E2, NF-κB, MAPK, ERK, PI3K/Akt/mTOR, YAP, Wnt/β‐catenin, Rho/ROCK, TGF‐β, VEGF, NO, iron, cytokines and chemokines. To find and develop novel medications for the treatment of EM, it is essential to implicitly determine the molecular pathways that are disordered during EM development. Additionally, research on the shared pathways between EM and tumors can provide hypotheses or suggestions for endometriosis therapeutic targets.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Adapted from “Top Design Tips for Drafting Your Graphical Abstracts”, by Biorender.com(2023). Retrieved from https://app.biorender.com/biorender-templates.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Endometriosis and tumors have many similar signaling pathways. |
• | Disordered signaling pathways should be studied in order to develop therapeutic drugs for endometriosis. |
• | Endometriosis has interplay between hormonal, inflammatory, and angiogenic factors. |
Abbreviation : CDDO-Me, ASK 1, ASC, ABC, BECN1, HES5, BPA, CAMs, CB, circRNAs, JNK, CHCHD2, ceRNA, DIE, DCs, DEHP, DNMTs, EP2, EFEMP1, ECS, EECs, ESCs, OMA, EM or EMs, ER, EMT, ERβ, ERE, ECM, ERK, EVs, FGA, FGFR2, FOX, GSH, GPX, GPX4, GCs, HH, HO, HK2, HMGB-1, HPF, HPMCs, HUVECs, HIF, IHEECs, IGF2-AS, IL-1β, JARID2, LTBP2, LIF, LSR, LXA4, lncRNAs, MDA, MCs, MPS-1, METTL3, MVD, MRP4, MDSCs, m6A, NADA, NOX, NIK, 7nAChR, NO, NLRP3, NSAIDs, OPN, oxLDL, SPP-1, PMN, PP2Ac, P4, PD-1, PDCD4, PD-L1, PGRN, PRM, PAR2, PKB, PPM1A, PDH, QoL, RAP1, ROS, ROCK, RUNX3, 7TM, SHP-1, STAT1, SIRP, SPHK, S1P, STING, SOD, TGIF1, TGF-β1, TRPV, TRIM, tRFs, tsRNAs, VNS, VEGF, YAP
Keywords : Endometriosis, Pathophysiology, Pathways, Targets
Plan
Vol 164
Article 114909- août 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?